StockData
Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc. (VERA) stock

VERANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$25.58−0.62 (-2.37%)

Close on Nov 18, 2026Market cap $1.84BP/E –Yield –

Vera Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Vera Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$338.91M. For fiscal 2025 it was -$241.73M. The highest annual figure on record is -$23.71M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$241.73M–
FY2024Dec 31, 2024-$135.65M–
FY2023Dec 31, 2023-$92.24M–
FY2022Dec 31, 2022-$67.66M–
FY2021Dec 31, 2021-$23.71M–
FY2020Dec 31, 2020-$34.91M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$100.25M–
Q1 FY2026Mar 31, 2026-$106.52M–
Q4 FY2025Dec 31, 2025-$70.10M–
Q3 FY2025Sep 30, 2025-$62.04M–
Q2 FY2025Jun 30, 2025-$55.01M–
Q1 FY2025Mar 31, 2025-$54.59M–
Q4 FY2024Dec 31, 2024-$39.83M–
Q3 FY2024Sep 30, 2024-$37.12M–
Q2 FY2024Jun 30, 2024-$24.87M–
Q1 FY2024Mar 31, 2024-$33.83M–
Q4 FY2023Dec 31, 2023-$25.21M–
Q3 FY2023Sep 30, 2023-$22.97M–
Q2 FY2023Jun 30, 2023-$17.77M–
Q1 FY2023Mar 31, 2023-$26.29M–
Q4 FY2022Dec 31, 2022-$21.16M–
Q3 FY2022Sep 30, 2022-$18.46M–
Q2 FY2022Jun 30, 2022-$19.04M–
Q1 FY2022Mar 31, 2022-$9.00M–
Q4 FY2021Dec 31, 2021-$6.44M–
Q3 FY2021Sep 30, 2021-$5.48M–
Q2 FY2021Jun 30, 2021-$7.67M–
Q1 FY2021Mar 31, 2021-$4.12M–
Q4 FY2020Dec 31, 2020-$27.38M–
Q3 FY2020Sep 30, 2020-$2.45M–
Q2 FY2020Jun 30, 2020-$2.72M–
Q1 FY2020Mar 31, 2020-$2.36M–

More Vera Therapeutics figures

See a number that looks wrong?